RxDoctor Payments DataLook up a doctor →

Laura Hummers, MD

Rheumatology · Baltimore, MDNPI 1104879527

Payments from drug & device makers

$1,040,889in general payments, 2019–2025

Across 288 payments — averaging $3614.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$336K
  • AstraZeneca$162K
  • GSK$125K
  • Tanabe Pharma America, Inc.$96K
  • Cumberland Pharmaceuticals, Inc.$91K
  • Amgen$69K
  • plus $162K from 12 others
$4,280in research payments, 2019–2025

Across 11 payments — averaging $389.12 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$3K
  • GSK$2K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,040,889 in reported general payments places this provider in the 95th percentile of 173 rheumatology providers in Maryland.

See all rheumatology providers in Maryland

Medicare billing

Part B allowed, 2024
$38,603
Medicare patients
157
Services billed
417

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other rheumatology in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →